About: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article (publication date: 24 July 2010)

Attributes	Values
rdf:type	Item
description	artículu científicu espublizáu en 2010 (ast) ശാസ്ത്രപ്രബന്ധം (ml) наукова стаття, опублікована в липні 2010 (uk) 2010 թվականի հուլիսին հրատարակված գիտական հոդված (hy) 2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած (hyw) article publié dans la revue scientifique The Lancet (fr) im Juli 2010 veröffentlichter wissenschaftlicher Artikel (de) مقالة علمية (نشرت في 24-7-2010) (ar) scientific article (publication date: 24 July 2010) (en) wetenschappelijk artikel (gepubliceerd op 2010/07/24) (nl)
publication date	wds:Q29619615-98DEE22E-7FDA-4A48-B566-F7343C3962D9
publication date	2010-07-24 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q29619615-7BD5D113-82AB-483E-9ED6-C3EF14F934D5
language of work or name	English
cites work	wds:Q29619615-00E3913F-0AD6-40E2-9EE4-38C39C89B495 wds:Q29619615-05684D98-94A6-4B78-A381-31984E13DBB6 wds:Q29619615-0CB65A39-E53C-4967-A9F4-CE81CE0624A3 wds:Q29619615-171DAE0B-2633-4558-8A38-7D4152E46A84 wds:Q29619615-1EAE75AE-A027-479F-813C-E5841B146111 wds:Q29619615-22621B2A-DA4D-44BE-9A2D-09296B315C51 wds:Q29619615-22F8FFD5-BEE7-409B-A10B-3FD472894FB7 wds:Q29619615-233FBD3F-8F24-42EB-A118-080B6D690791 wds:Q29619615-29E5D157-EE98-4D31-B604-26B78C30B907 wds:Q29619615-2B7011BE-9B1B-4273-84DB-14303D28D8F1 wds:Q29619615-3948F01A-B25B-45FF-B2D3-FAD43446F0AC wds:Q29619615-4048D92D-BE53-4B9A-B3C8-CF0929E4CBC4 wds:Q29619615-6BDB589C-6767-4397-975E-396E6E5CCDFF wds:Q29619615-7393F6CE-36B7-4E91-927C-111E744D5BB8 wds:Q29619615-743BE257-BC46-4DA7-9D52-420C6EE6EDC0 wds:Q29619615-892B8D94-FE88-4DC5-9D97-2CD2AE360912 wds:Q29619615-AA03166F-2A50-4167-8F73-518718393959 wds:Q29619615-AD683C7F-C117-4640-825E-020124109893 wds:Q29619615-BBE254B5-9F1E-4374-9AE2-CBBEC8F218B8 wds:Q29619615-D44A22BD-2E33-418E-915F-A9E22E8D8B96 wds:Q29619615-DBF997FF-978B-4158-88B0-BE53098F1D45 wds:Q29619615-DC60EAFA-7594-47C7-B04B-081B7FEC7F11 wds:Q29619615-DE4C8AAB-764D-41EE-9FBA-251C264E7EC0 wds:Q29619615-E3D4683A-B336-45D4-BEF2-114115A1C7F4 wds:Q29619615-E6ADA185-A1D9-4C13-AD97-8260990FCA31 wds:Q29619615-E74038BF-D4F5-4CA3-B9D5-597CB78B436B
cites work	Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair BRCA2 is required for homology-directed repair of chromosomal breaks The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada The concept of synthetic lethality in the context of anticancer therapy Resistance to therapy caused by intragenic deletion in BRCA2 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Brca1 controls homology-directed DNA repair Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition The PARP superfamily Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma BRCA1 and BRCA2 in breast cancer Preventing future cancers by testing women with ovarian cancer for BRCA mutations Efficient Deletion of NormalBrca2-Deficient Intestinal Epithelium by Poly(ADP-Ribose) Polymerase Inhibition Models Potential Prophylactic Therapy
author name string	wds:Q29619615-4277E216-6EAF-4A33-B0A0-7FF2FB7BFF28 wds:Q29619615-4BD65056-E482-4575-9E12-EC89D72EB9E2 wds:Q29619615-57E1C921-4939-4D0D-AC71-E10AA3ECB359 wds:Q29619615-6CCD5C25-BDD5-4AEA-BBB9-75D8A83BE3BE wds:Q29619615-771B81D3-20E6-487C-96F4-6916D4A0479C wds:Q29619615-8612952F-C532-4266-934B-02E82DA87119 wds:Q29619615-CA154636-AC0D-4CDD-B263-2689B17A7110 wds:Q29619615-D381EA23-587A-4AB3-AF79-A7E7AC595392 wds:Q29619615-DEF3D32F-C793-49A1-B789-E227AC3A6962 wds:Q29619615-E4A5C01F-B3EF-4A5A-8EF8-883BE0F3552E wds:Q29619615-EC0F2E85-A79E-4B4C-849E-CF11F45D5BAA wds:Q29619615-F1163805-750E-4709-967C-2858389831E3 wds:Q29619615-FDCCA7BF-C625-423E-BB86-0CDA16A437F1
OpenCitations bibliographic resource ID	wds:Q29619615-989E4C35-A023-4727-98C3-9C93BF869CFC
OpenCitations bibliographic resource ID	https://w3id.org/oc/corpus/br/1724576
author name string	Scott C Tutt A Wickens M Lu K Carmichael J Powell B Matulonis U Friedlander M Penson RT Loman N Audeh MW Oaknin A Bell-McGuinn KM
OpenCitations bibliographic resource ID	1724576
rdfs:label	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial (en) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial (ast)
skos:prefLabel	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial (en) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial (ast)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software